ArticleJournal of cardiothoracic surgery2026
Clinical role and mechanism of miR-4443 in coronary heart disease: a prognostic marker and regulator of vascular smooth muscle cell Function.
Article in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDysregulation of vascular smooth muscle cell (VSMC) function is a key factor in coronary heart disease (CHD) pathogenesis. This study investigates the role of miR-4443 in regulating VSMC behavior and its potential as a clinical biomarker.
methodsClinical data from 200 CHD patients were retrospectively analyzed. miR-4443 expression levels were quantified via RT-qPCR in paired plasma specimens and in VSMC exposed to oxidized low-density lipoprotein (ox-LDL). Prognostic relevance was evaluated through Kaplan-Meier analysis and multivariate Cox regression modeling. Cellular transfection, CCK-8, Transwell, and dual-luciferase reporter assays were employed to evaluate VSMC proliferation, migration, and gene regulatory mechanisms.
resultsCHD patients exhibited significantly higher serum levels of miR‑4443 relative to healthy controls. Univariate analysis revealed significant associations between the risk of major adverse cardiovascular events (MACEs) and miR‑4443, BMI, LDL‑C, and CRP. After multivariable adjustment, elevated miR‑4443 expression retained independent prognostic value for adverse outcomes (HR = 2.812, 95% CI: 1.130-6.997, P = 0.026). Kaplan-Meier analysis revealed an elevated cumulative incidence of MACEs in patients exhibiting high miR-4443 levels relative to those with low expression. In ox-LDL-induced VSMCs, miR-4443 expression was upregulated. Functionally, miR-4443 promoted VSMC proliferation and migration, while its inhibition suppressed these processes. TIMP2 expression was reduced in CHD patients. Furthermore, luciferase reporter assays confirmed TIMP2 as a direct target of miR-4443, through which miR-4443 regulates VSMC function.
conclusionmiR-4443 functions as a prognostic biomarker in CHD by targeting TIMP2 to regulate VSMC proliferation and migration, highlighting its dual diagnostic and therapeutic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.